A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases.
A single-center study of 11 patients with intraocular lymphoma treated with conventional chemotherapy followed by high-dose chemotherapy and autologous bone marrow transplantation in 5 cases.
复制标题
一项单中心研究，对11例眼内淋巴瘤患者进行常规化疗，随后进行大剂量化疗，并进行自体骨髓移植5例。
DOI：
10.3109/10428199609054837
复制
发表时间：
1996
影响因子：
2.6
通讯作者：
V. Leblond
中科院分区：
文献类型：
--
作者：
C. Soussain;H. Merle;I. Reux;L. Sutton;C. Fardeau;Sophie Gerber;T. Othman;J. Binet;P. Lehoang;V. Leblond
眼内淋巴瘤 (IOL) 是一种罕见的非霍奇金淋巴瘤 (NHL)；它的预后很差，并且经常与中枢神经系统（CNS）浸润有关。我们报告了一项前瞻性研究的结果，该研究对 11 名 IOL 患者进行了常规化疗 (CT)，随后对 5 例患者进行了挽救性高剂量 (HD) CT 联合自体骨髓移植 (ABMT)。所有 11 名患者的眼底镜检查结果均异常，其中 6 名患者在诊断时有中枢神经系统受累。诊断依据为玻璃体切除术10例，脑立体定位活检1例。病理学研究显示所有病例均为大细胞 NHL。这些大细胞 NHL 8 例为 B 细胞型，2 例为 T 细胞型。一线治疗包括顺铂 25 mg/m2 连续 4 天 24 小时静脉输注，VP-16 40 mg/m2 持续 4 天，阿糖胞苷 2 g/m2 第 5 天静脉滴注，甲基强的松龙 500 mg 静脉输注每天 5 天（ESHAP），其中 5 例； ESHAP与HD甲氨蝶呤（MTX）交替疗程4例； 2例为HD MTX。三名患者接受了眼部和全脑放射治疗。 5 名难治性患者随后接受了强化 CT 治疗，使用塞替派 750 mg/m2、白消安 10 mg/kg 和环磷酰胺 120 mg/kg，随后进行 ABMT。 10 例可评估病例一线治疗失败。一名患者在 12 个月时死于中枢神经系统进展。接受强化CT和ABMT治疗的患者全部进入CR；两名患者在 6 个月时复发，三名患者在 ABMT 后 15、15 和 14 个月时仍存活。 6 名患者在 8、13、14、15、18 和 24 个月时仍处于疾病持续状态。结论似乎是，高剂量塞替派、白消安和环磷酰胺，然后进行 ABMT 对于某些难治性 IOL 病例是有效的。
Intraocular lymphoma (IOL) is a rare form of non Hodgkin lymphoma (NHL); it has a poor prognosis and is frequently associated with central nervous system (CNS) infiltration. We report the results of a prospective study of 11 patients with IOL who received conventional chemotherapy (CT), followed by salvage high-dose (HD) CT with autologous bone marrow transplantation (ABMT) in five cases. All 11 patients had abnormal funduscopic findings and six had CNS involvement at diagnosis. The diagnosis was based on vitrectomy in 10 cases and cerebral stereotaxic biopsy in one. Pathologic studies showed large-cell NHL in all cases. These large-cell NHL were of the B-cell type in 8 cases and of the T-cell type in two. First-line therapy consisted of a combination of cisplatin 25 mg/m2 as a 24-hour IV infusion on 4 consecutive days, VP-16 40 mg/m2 for 4 days, aracytine 2 g/m2 IV on day 5, and methylprednisolone 500 mg IV daily for 5 days (ESHAP) in 5 cases; alternating courses of ESHAP and HD methotrexate (MTX) in 4 cases; and HD MTX in 2 cases. Three patients underwent ocular and whole-brain radiation therapy. Five refractory patients subsequently received intensive CT with thiotepa 750 mg/m2, busulfan 10 mg/kg and cyclophosphamide 120 mg/kg, followed by ABMT. First-line treatment failed in 10 evaluable cases. One patient died of CNS progression at 12 months. All the patients who underwent intensive CT and ABMT entered CR; two relapsed at 6 months and three are alive in CR 15, 15 and 14 months after ABMT. Six patients are alive with persistent disease at 8, 13, 14, 15, 18 and 24 months. It seems in conclusion that, high-dose thiotepa, busulfan and cyclophosphamide followed by ABMT is effective in some cases of refractory IOL.
高剂量卡莫司汀、依托泊苷和顺铂以及自体骨髓移植治疗复发性和难治性淋巴瘤。
DOI：
10.1200/jco.1992.10.11.1682
发表时间：
1992
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Lazarus,HM;Crilley,P;Ciobanu,N;Creger,RJ;Fox,RM;Shina,DC;Bulova,SI;Gucalp,R;Cooper,BW;Topolsky,D
通讯作者：
Topolsky,D